...
首页> 外文期刊>Nutrition and Cancer: An International Journal >Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study.
【24h】

Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study.

机译:西兰花芽中的芥子油苷和异硫氰酸盐的安全性,耐受性和代谢:I期临床研究。

获取原文
获取原文并翻译 | 示例

摘要

Broccoli sprouts are widely consumed in many parts of the world. There have been no reported concerns with respect to their tolerance and safety in humans. A formal phase I study of safety, tolerance, and pharmacokinetics appeared justified because these sprouts are being used as vehicles for the delivery of the glucosinolate glucoraphanin and its cognate isothiocyanate sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] in clinical trials. Such trials have been designed to evaluate protective efficacy against development of neoplastic and other diseases. A placebo-controlled, double-blind, randomized clinical study of sprout extracts containing either glucosinolates (principally glucoraphanin, the precursor of sulforaphane) or isothiocyanates (principally sulforaphane) was conducted on healthy volunteers who were in-patients on our clinical research unit. The subjects were studied in three cohorts, each comprising three treated individuals and one placebo recipient. Following a 5-day acclimatization period on a crucifer-free diet, the broccoli sprout extracts were administered orally at 8-h intervals for 7 days (21 doses), and the subjects were monitored during this period and for 3 days after the last treatment. Doses were 25 micromol of glucosinolate (cohort A), 100 micromol of glucosinolate (cohort B), or 25 micromol of isothiocyanate (cohort C). The mean cumulative excretion of dithiocarbamates as a fraction of dose was very similar in cohorts A and B (17.8 +/- 8.6% and 19.6 +/- 11.7% of dose, respectively) and very much higher and more consistent in cohort C (70.6 +/- 2.0% of dose). Thirty-two types of hematology or chemistry tests were done before, during, and after the treatment period. Indicators of liver (transaminases) and thyroid [thyroid-stimulating hormone, total triiodothyronine (T3), and free thyroxine (T4)] function were examined in detail. No significant or consistent subjective or objective abnormal events (toxicities) associated with any of the sprout extract ingestionswere observed.
机译:西兰花芽在世界许多地方被广泛食用。没有关于它们在人类中的耐受性和安全性的报道。一项正式的关于安全性,耐受性和药代动力学的I期研究似乎是有道理的,因为这些新芽在临床上已被用作运送芥子油苷,葡糖精及其同源异硫氰酸盐硫氰酸盐[1-isothiocyanato-(4R)-(甲基亚磺酰基)丁烷]的载体审判。设计此类试验的目的是评估针对肿瘤性疾病和其他疾病发展的保护作用。对在我们临床研究部门住院的健康志愿者进行了安慰剂对照,双盲,随机试验,试验研究了含有芥子油苷(主要是萝卜硫素的前体),芥子油苷或异硫氰酸酯(主要是萝卜硫素)的新芽提取物。在三个队列中对受试者进行了研究,每个队列包括三个治疗个体和一个安慰剂接受者。在无十字花科饮食的环境中适应5天后,将西兰花芽提取物以8小时间隔口服7天(21剂),并在此期间以及最后一次治疗后的3天对受试者进行监测。剂量为25微摩尔芥子油苷(队列A),100微摩尔芥子油苷(队列B)或25微摩尔异硫氰酸酯(队列C)。组A和组B中二硫代氨基甲酸盐的平均累积排泄量与剂量非常相似(分别为剂量的17.8 +/- 8.6%和19.6 +/- 11.7%),在组C中则更高且更一致(70.6 +/- 2.0%的剂量)。在治疗前,治疗中和治疗后进行了32种血液学或化学测试。详细检查了肝(转氨酶)和甲状腺的指标[促甲状腺激素,总三碘甲状腺素(T3)和游离甲状腺素(T4)]功能。没有观察到与摄入任何新芽提取物相关的显着或一致的主观或客观异常事件(毒性)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号